Psychedelic Drugs Market to Reach $12.89 Billion by 2035, Growing at 15% CAGR | MindMed, Janssen Pharmaceuticals, Lykos Therapeutics Among Key Players

The global psychedelic drugs market, valued at USD 2.77 billion in 2024, is on course to reach USD 3.19 billion in 2025 and USD 12.89 billion by 2035, advancing at a compound annual growth rate of 15% over the forecast period. Surging rates of treatment-resistant depression, PTSD, and anxiety disorders are pushing clinicians and investors toward psychedelic-assisted therapies that conventional pharmaceutical options have repeatedly failed to address. The combination of widening clinical evidence, high-profile M&A activity, and shifting regulatory posture makes this one of the more consequential growth stories in the broader mental health sector.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market/request-sample.html

Market Overview
The psychedelic drugs market centers on the clinical development and commercialization of compounds including psilocybin, MDMA, ketamine, and gamma-hydroxybutyrate, administered under controlled therapeutic conditions to treat psychiatric and neurological disorders. Unlike recreational use, psychedelic-assisted therapy pairs pharmacological intervention with structured psychotherapeutic support, a model that Phase II and Phase III clinical data are increasingly validating.

The urgency driving investment into this space is not difficult to quantify. Mental health disorders linked to inadequate treatment options cost the global economy more than USD 1 trillion annually in lost productivity. During the COVID-19 lockdown period alone, prescriptions for antidepressants and anti-anxiety medications in the United States climbed by approximately 20%, signaling how severely existing treatment infrastructure is strained. The World Health Organization has identified persistent stigma, diagnostic inaccuracy, and a shortage of effective pharmacotherapies as core barriers to resolving this burden, and psychedelic-assisted approaches are being evaluated as a structural answer to each of these gaps.

Corporate activity in this market has accelerated materially in the past twelve months. In October 2025, AbbVie announced its acquisition of Gilgamesh Pharmaceuticals' bretisilocin program, a next-generation psychedelic compound in Phase II development for major depressive disorder, for up to USD 1.2 billion. That same period saw Atai Life Sciences complete an all-stock merger with Beckley Psytech at a USD 370 million valuation, forming AtaiBeckley, a combined entity advancing a 5-MeO-DMT candidate for mental health disorders. These transactions signal that large pharmaceutical companies are no longer treating psychedelic therapeutics as fringe science.

Key Growth Drivers
Rising Prevalence of Treatment-Resistant Mental Health Conditions. More than 300 million individuals worldwide live with depression, and a meaningful proportion do not respond adequately to first- or second-line pharmacotherapy. PTSD, addiction, and anxiety disorders compound the clinical unmet need. Psychedelic compounds, particularly MDMA and psilocybin, have shown rapid and durable effects in patients who failed multiple prior treatment courses, making the therapeutic case for continued development compelling.

Strengthening Clinical Evidence Base. Phase II and Phase III trial results across multiple programs are producing the kind of statistically significant, reproduced efficacy data that changes prescriber and regulator behavior. MindMed's MM120 ODT, an orally disintegrating lysergide formulation, entered a Phase III study in 2025 after Phase 2b data demonstrated rapid anxiolytic and antidepressant-like effects in generalized anxiety disorder. Psilocybin trials in addiction and end-of-life distress contexts are generating similarly positive signals, widening the addressable indication set.

Supportive Regulatory Evolution. North American regulators have moved from cautious observation to active engagement with psychedelic drug development. Breakthrough Therapy Designations from the FDA have been granted to multiple programs, accelerating review timelines. Several U.S. states have created legal frameworks for supervised psilocybin therapy, establishing real-world delivery infrastructure that will inform broader regulatory policy.

Substantial Investment and M&A Activity. Developers in this space have collectively received over USD 275 million in academic grants, supplementing venture capital and strategic acquisition dollars. AbbVie's USD 1.2 billion commitment to bretisilocin and the Atai-Beckley merger demonstrate that capital is moving from exploratory investment into large-scale commercialization bets. This financial momentum is bringing professional drug development infrastructure to what was, five years ago, a largely academic field.
Shifting Public and Clinical Attitudes. As Manish Agrawal, Co-founder and CEO of Sunstone Therapies, noted at the Psychedelic Science Conference 2025, oncologists and other specialists who historically held psychedelic-assisted therapy at arm's length are now actively engaging with the evidence. This attitudinal shift, driven by published clinical data and increased public awareness, is expanding the referral base and accelerating patient access pipelines.

Market Segmentation
Within the psychedelic drugs market, ketamine commands the largest share by type of substance in 2025. Its established FDA approval for treatment-resistant depression via esketamine nasal spray (Spravato), existing clinical familiarity among psychiatrists, and well-understood safety profile give it a head start over other compounds. However, psilocybin is the fastest-growing sub-segment and is forecast to expand at a relatively higher CAGR through 2035, driven by its increasing use across addiction, PTSD, and anxiety indications and its expanding trial presence. MDMA and gamma-hydroxybutyrate occupy distinct niches within trauma and sleep-related disorders, respectively. Across disease indications, post-traumatic stress disorder is projected to capture the largest share of the overall market, reflecting the convergence of regulatory progress, clinical momentum, and the high unmet need in that population. By route of administration, oral delivery leads, with intranasal and sublingual routes supporting specific branded formulations.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market/request-quote.html

Regional Insights
North America holds the dominant position in the global psychedelic drugs market and is projected to maintain the majority of overall market share through 2035. The region benefits from a high prevalence of diagnosed mental health conditions, a well-capitalized pharmaceutical development ecosystem, and the most advanced regulatory infrastructure for psychedelic therapies anywhere in the world. FDA Breakthrough Therapy Designations for multiple compounds and state-level legal frameworks for supervised psilocybin services have created a structural advantage that other regions have not yet replicated.

Europe holds the second-largest share, accounting for approximately 23% of developer company headquarters in this market. Regulatory activity in the United Kingdom and the Netherlands, alongside academic research programs at leading universities, is generating a credible pipeline of European-originated clinical assets. The Asia-Pacific region represents the smallest current share at roughly 6% of developer presence, but the combination of large patient populations, growing psychiatric diagnosis rates, and increasing government investment in mental health infrastructure positions it as a meaningful growth market over the second half of the forecast window.

Competitive Landscape
The current psychedelic drugs market features more than 70 companies, with 71% headquartered in North America and the remainder distributed primarily across Europe (23%) and Asia-Pacific (6%). Key players profiled in the Roots Analysis report include Celon Pharma, iX Biopharma, Lykos Therapeutics, MindMed, Janssen Pharmaceuticals, and Jazz Pharmaceutical, among others.

The market is still in a formative stage, but consolidation is clearly beginning. Large pharmaceutical companies are acquiring early-stage psychedelic programs rather than building in-house capability, as AbbVie's Gilgamesh acquisition and the Atai-Beckley merger both illustrate. For smaller developers, the primary competitive battleground is clinical differentiation, specifically, demonstrating superior duration of effect, lower side-effect burden, or shorter administration time compared to existing approved options. Intellectual property around novel formulations, such as MindMed's proprietary orally disintegrating tablet format for MM120, is becoming a key dimension of competitive strategy as the pipeline matures toward commercialization.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.